HER2+ Gastric Cancer Market Size, Share, Industry Trends, Key Players, and Forecast through 2024-2031

Global HER2+ Gastric Cancer Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing with a CAGR of YY% during the forecast period 2024-2031.

HER2+ Gastric Cancer Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/her2-gastric-cancer-market?sg

HER2 overexpression is increasingly recognized as a common molecular abnormality, often driven by gene amplification, as seen in breast cancer. Growing evidence links HER2 overexpression in gastric cancer to more aggressive disease and poorer patient outcomes. HER2-positive gastric cancer, a distinct subtype characterized by excessive HER2 protein expression, has shown improved prognosis with targeted HER2 therapies, highlighting the significance of personalized treatment approaches.

List of the Key Players in the HER2+ Gastric Cancer Market: Astrazeneca, Genentech USA, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm, Shanghai Henlius Biotech, Sanofi, Pfizer and Novartis AG.

Industry Development:

In November 2023, Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd jointly stated, that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) granted a Breakthrough Therapy designation to KN026 (HER2 bispecific antibody) combined with chemotherapy for the treatment of HER2-positive gastric cancer (including gastroesophageal junction cancer).

In December 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

Growth Forecast Projected:

The Global HER2+ Gastric Cancer Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global HER2+ Gastric Cancer Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/her2-gastric-cancer-market?sg

Segment Covered in the HER2+ Gastric Cancer Market:

By Therapy (Immunotherapy, Chemotherapy, Radiation Therapy, Targeted Therapy)

By Stage (Stage I, Stage II, Stage III, Stage IV)

By End User (Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Others)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Regional Analysis for HER2+ Gastric Cancer Market:

The regional analysis of the HER2+ Gastric Cancer Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

➡ Top-down and bottom-up approach for regional analysis

➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Browse More Reports:

Helicobacter Pylori Infection Therapeutics Market - https://datamintelligence.com/research-report/helicobacter-pylori-infection-therapeutics-market?sg

Barett Esophagus Treatment Market - https://datamintelligence.com/research-report/barett-esophagus-treatment-market?sg

Cholecystitis Treatment Market - https://datamintelligence.com/research-report/cholecystitis-treatment-market?sg

People Also Ask:

➠ What is the global sales, production, consumption, import, and export value of the HER2+ Gastric Cancer market?

➠ Who are the leading manufacturers in the global HER2+ Gastric Cancer industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

➠ What opportunities and challenges do vendors in the global HER2+ Gastric Cancer industry face?

➠ Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

➠ What are the key factors and limitations affecting the growth of the HER2+ Gastric Cancer market?

➠ What are the various sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.